Draft:Axicabtagene ciloleucel

Global CAR T Cell Therapy Market 2016-2026: The Most Hot Topic Discussed Among Oncologists Throughout the Globe

Retrieved on: 
星期四, 六月 14, 2018
Medicine, Health, Breakthrough therapy, Clinical medicine, Cancer treatments, Axicabtagene ciloleucel, Immunosuppressants, Gene therapy, Tocilizumab, Tisagenlecleucel, Therapy, Draft:Axicabtagene ciloleucel

The global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2017 to 2025.

Key Points: 
  • The global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2017 to 2025.
  • CAR T cell therapy is the most hot topic discussed among oncologist throughout the globe.
  • The FDA approved CAR T cell therapy are Tisagenleucel (Kymriah), Axicabtagene ciloleucel (Yescarta) and Tocilizumab (Actemra).
  • Global CAR T Cell Therapy Market, by Geography, 2017 (US$ Mn)
    Chapter 3.

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Retrieved on: 
星期二, 五月 1, 2018
Medicine, Cancer, RTT, Lymphoma, Gene therapy, Clinical medicine, Non-Hodgkin lymphoma, T cells, Chimeric antigen receptor, Tisagenlecleucel, Hodgkin's lymphoma, Draft:Axicabtagene ciloleucel

Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.

Key Points: 
  • Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.
  • Kymriah is now the only CAR-T cell therapy to receive FDA approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B-cell ALL.
  • Kymriah is an innovative immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient's own T cells.
  • The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Kymriah treatment.